2 results  1 of 1 

1 Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Xueying Li, He Huang, Bing Xu, Hongqiang Guo, Yingcheng Lin, Sheng Ye, Jiqun Yi, Wenyu Li, Xiangyuan Wu, Wei Wang, Hongyu Zhan, Derong Xie, Jiewen Peng, Yabing Cao, Xingxiang Pu, Chengcheng Guo, Huangming Hong, Zhao Wang, Xiaojie Fang, Yong Zhou, Suxia Lin, Qing Liu, Tongyu Lin
Cancer Res Treat.2019;51(3):919-932.   Published online 2018 October 2     DOI: http://dx.doi.org/10.4143/crt.2018.230
      
2 A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
Jeong Eun Kim, Dok Hyun Yoon, Geundoo Jang, Dae Ho Lee, Shin Kim, Chan-Sik Park, Jooryung Huh, Won Seog Kim, Jinny Park, Jae Hoon Lee, Soon Il Lee, Cheolwon Suh
Korean J Hematol.2012;47(1):53-59.   Published online 2012 March 28     DOI: http://dx.doi.org/10.5045/kjh.2012.47.1.53
      

 1 of 1